OVERALL Abstract The Michigan Alzheimer?s Disease Core Center (Michigan ADCC) aims to foster and enhance innovative research in Alzheimer?s disease (AD) and related dementias with a long term goal of developing targeted therapies for these challenging disorders. This center will build on the existing deep infrastructure and research strengths in dementia and aging research at the University of Michigan (UM). The Michigan ADCC will emphasize research that seeks to identify, understand, and modulate the non--amyloid factors that contribute to brain dysfunction and neurodegeneration in AD and other dementias. The rationale for this focus is that while recent advances have defined a central role for -amyloid in AD, many potentially modifiable factors beyond -amyloid contribute to brain dysfunction and degeneration yet remain poorly understood. The Michigan ADCC will leverage established strengths in brain imaging, dementia risk identification and disclosure, mechanistic studies of neurodegenerative proteinopathies, and predictive Big Data analytics to achieve this objective. A truly regional center, the Michigan ADCC will promote research across the UM campus, throughout the state of Michigan via collaborations with our partner universities Michigan State University and Wayne State University, and across the nation through collaborations with other NIA-sponsored AD Centers (ADCs) and programs. The Michigan ADCC has four goals: 1) Foster, catalyze and perform research of the highest potential impact in AD and related neurodegenerative disorders; 2) Promote regional efforts to understand, diagnose and treat AD and related dementias through collaborative scientific and outreach efforts; 3) Provide a wide range of training and research opportunities in the dementias for health care professionals, scientists, and students through innovative educational and mentoring efforts; and 4) Collaborate with other ADCs, the NACC, and other multi-center research efforts to move the field closer to effective therapies for this group of devastating diseases. Success in achieving these goals will be ensured through the fully integrated activities of six cores (Administrative; Clinical; Data Management and Statistical; Neuropathology; Outreach and Recruitment; and Research Education Component ), and through close collaboration with related programs including the UM Protein Folding Diseases Initiative, Claude D. Pepper Older Americans Independence Center, Udall Center of Excellence for Parkinson?s Disease Research, and Healthier Black Elders Center of the Michigan Center for Urban African American Aging Research. These and other collaborations have led to newly developed emphases on the detection of early cognitive decline in an underserved population (African Americans in Detroit) and on novel potential biomarkers of disease. The Center?s extensive preliminary organization and teams of experts ensure that, upon receiving NIA designation, the Michigan ADCC will have an immediate impact, both regionally and nationally, in enhancing research to better understand and treat AD and related forms of dementia.

Public Health Relevance

Alzheimer's Disease (AD) and related dementias represent one of the fastest growing health problems in the United States and in the state of Michigan. Building on longstanding strengths in dementia research at the University of Michigan (UM) and facilitated by partnership with the state of Michigan?s two other major research universities, Michigan State University and Wayne State University, the Michigan ADCC will lead a regional effort to identify, understand and modulate the many non- amyloid factors that contribute to brain dysfunction and degeneration in AD and related dementias.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
1P30AG053760-01
Application #
9172095
Study Section
Special Emphasis Panel (ZAG1-ZIJ-G (M1))
Program Officer
Silverberg, Nina B
Project Start
2016-08-15
Project End
2021-06-30
Budget Start
2016-08-15
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$1,719,170
Indirect Cost
$589,915
Name
University of Michigan Ann Arbor
Department
Neurology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Tiernan, Chelsea T; Ginsberg, Stephen D; He, Bin et al. (2018) Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiol Dis 117:125-136
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Hampstead, Benjamin M; Towler, Stephen; Stringer, Anthony Y et al. (2018) Continuous measurement of object location memory is sensitive to effects of age and mild cognitive impairment and related to medial temporal lobe volume. Alzheimers Dement (Amst) 10:76-85
Lichtenberg, Peter A; Ocepek-Welikson, Katja; Ficker, Lisa J et al. (2018) Conceptual and Empirical Approaches to Financial Decision-making by Older Adults: Results from a Financial Decision-making Rating Scale. Clin Gerontol 41:42-65
Singer, Benjamin H; Dickson, Robert P; Denstaedt, Scott J et al. (2018) Bacterial Dissemination to the Brain in Sepsis. Am J Respir Crit Care Med 197:747-756
Malik, Ahmed M; Miguez, Roberto A; Li, Xingli et al. (2018) Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. Elife 7:
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 106 publications